Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, was honored as one of the “Top 25 Biotech & Life Sciences Companies for 2025” by The Healthcare Technology Report. This award is highly regarded by corporate executives, institutional investors, and industry leaders, cementing Immunis’ reputation as a groundbreaking force in biomedical innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814694848/en/
The Healthcare Technology Report (HTR) is a respected market research firm that reports on the developments, corporate actions, investment activity, and executive insights related to the healthcare industry. Awardees are chosen following an intensive evaluation of product innovation, leadership, strategic impact, and contributions to the global advancement of patient healthcare. Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans. Not only does Immunis have the most clinically advanced secretome therapy in the world, but it is also tackling one of the most challenging health issues for which there is no pharmaceutical cure.
Impressively, Immunis is recognized alongside some of the industry’s most influential biotech companies that are invoking actionable change in human healthcare. The coveted distinction inspires Immunis to continue revolutionizing patient-centered biotechnology and dismantling barriers towards its progress.
Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived biologics for the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis’ leading-edge capabilities in stem cell secretome technology to deliver a product of all natural, all human immune modulators in their natural physiological concentrations.
For additional information about Immunis’ programs, please visit our Pipeline.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250814694848/en/
Immunis received the accolade based on the ingenuity of its investigational stem cell-derived secretome therapy, IMM01-STEM, which aims to address age–related muscle atrophy, a disease that will affect 100% of humans.
